Salivary IgA to MAA-LDL and Oral Pathogens Are Linked to Coronary Disease.

atherosclerosis bacterial virulence biomarkers lipids mucosal immunity periodontal disease(s)/periodontitis

Journal

Journal of dental research
ISSN: 1544-0591
Titre abrégé: J Dent Res
Pays: United States
ID NLM: 0354343

Informations de publication

Date de publication:
03 2019
Historique:
pubmed: 24 1 2019
medline: 30 1 2020
entrez: 24 1 2019
Statut: ppublish

Résumé

A large body of literature has established the link between periodontal disease and cardiovascular disease. Oxidized low-density lipoproteins (OxLDLs) have a crucial role in atherosclerosis progression through initiation of immunological response. Monoclonal IgM antibodies to malondialdehyde-modified low-density lipoprotein (MDA-LDL) and to malondialdehyde acetaldehyde-modified low-density lipoprotein (MAA-LDL) have been shown to cross-react with the key virulence factors of periodontal pathogens Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans. We have previously shown that salivary IgA antibodies to MAA-LDL cross-react with P. gingivalis in healthy humans. In this study, we aim to assess whether oral mucosal immune response represented by salivary IgA to MAA-LDL and oral pathogens is associated with coronary artery disease (CAD). Also, the molecular mimicry through antibody cross-reaction between salivary IgA to MAA-LDL and oral pathogens was evaluated. The study subjects consisted of 451 patients who underwent a coronary angiography with no CAD ( n = 133), stable CAD ( n = 169), and acute coronary syndrome (ACS, n = 149). Elevated salivary IgA antibody levels to MAA-LDL, Rgp44 (gingipain A hemagglutinin domain of P. gingivalis), and Aa-HSP60 (heat shock protein 60 of A. actinomycetemcomitans) were discovered in stable-CAD and ACS patients when compared to no-CAD patients. In a multinomial regression model adjusted for known cardiovascular risk factors, stable CAD and ACS were associated with IgA to MAA-LDL ( P = 0.016, P = 0.043), Rgp44 ( P = 0.012, P = 0.004), Aa-HSP60 ( P = 0.032, P = 0.030), Tannerella forsythia ( P = 0.002, P = 0.004), Porphyromonas endodontalis ( P = 0.016, P = 0.020), Prevotella intermedia ( P = 0.038, P = 0.005), and with total IgA antibody concentration ( P = 0.002, P = 0.016). Salivary IgA to MAA-LDL showed cross-reactivity with the oral pathogens tested in the study patients. The study highlights an association between salivary IgA to MAA-LDL and atherosclerosis. However, whether salivary IgA to MAA-LDL and the related oral humoral responses play a causal role in the development in the CAD should be elucidated in the future.

Identifiants

pubmed: 30669938
doi: 10.1177/0022034518818445
doi:

Substances chimiques

Immunoglobulin A 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

296-303

Auteurs

R Akhi (R)

1 Medical Microbiology and Immunology, Research Unit of Biomedicine, University of Oulu, Oulu, Finland.
2 Medical Research Center, Oulu University Hospital and University of Oulu, Oulu, Finland.
3 Nordlab, Oulu University Hospital, Oulu, Finland.

C Wang (C)

1 Medical Microbiology and Immunology, Research Unit of Biomedicine, University of Oulu, Oulu, Finland.
2 Medical Research Center, Oulu University Hospital and University of Oulu, Oulu, Finland.
3 Nordlab, Oulu University Hospital, Oulu, Finland.

A E Nissinen (AE)

1 Medical Microbiology and Immunology, Research Unit of Biomedicine, University of Oulu, Oulu, Finland.
2 Medical Research Center, Oulu University Hospital and University of Oulu, Oulu, Finland.
3 Nordlab, Oulu University Hospital, Oulu, Finland.

J Kankaanpää (J)

1 Medical Microbiology and Immunology, Research Unit of Biomedicine, University of Oulu, Oulu, Finland.
2 Medical Research Center, Oulu University Hospital and University of Oulu, Oulu, Finland.
3 Nordlab, Oulu University Hospital, Oulu, Finland.

R Bloigu (R)

4 Medical Informatics and Statistics Research Group Oulu, University of Oulu, Oulu, Finland.

S Paju (S)

5 Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

P Mäntylä (P)

5 Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
6 Institute of Dentistry, University of Eastern Finland, Kuopio, Finland.
7 Kuopio University Hospital, Oral and Maxillofacial Diseases, Kuopio, Finland.

K Buhlin (K)

5 Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
8 Division of Periodontology, Department of Dental Medicine, Karolinska Institutet, Huddinge, Sweden.

J Sinisalo (J)

9 HUCH Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.

P J Pussinen (PJ)

5 Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

S Hörkkö (S)

1 Medical Microbiology and Immunology, Research Unit of Biomedicine, University of Oulu, Oulu, Finland.
2 Medical Research Center, Oulu University Hospital and University of Oulu, Oulu, Finland.
3 Nordlab, Oulu University Hospital, Oulu, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH